{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T04:18:47Z","timestamp":1776745127875,"version":"3.51.2"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,2]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of the Report<\/jats:title>\n            <jats:p>Ovarian cancer is usually diagnosed in an advanced stage of disease due to the absence of specific symptoms and a lack of sensitive diagnostic methods. Prostate-specific membrane antigen (PSMA) is expressed on prostate cancer cells but can be found in other tumors such as ovarian cancer.<\/jats:p>\n            <jats:p>The aim of this pilot study was to evaluate the feasibility of using <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT in detection of ovarian neoplasm before surgical treatment.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Patients and Methods<\/jats:title>\n            <jats:p>Eight women with mean age of 56.0 \u00b1 16.2 years were included in the study. All patients underwent transvaginal ultrasound followed by CT scan of the chest and abdomen as qualification for surgery. Within a 1-week interval, PET\/CT was performed on a Siemens Biograph scanner, 60 minutes after injection of 2 MBq\/kg <jats:sup>68<\/jats:sup>Ga-PSMA-11.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>In 3 cases (37.5%), the <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT was positive, whereas histological examination confirmed 2 serous ovarian cancer cases and 1 ovarian borderline tumor. The SUV<jats:sub>max<\/jats:sub> in the serous ovarian cancer was 8.7 and 4.1, and in the borderline ovarian tumor, it was 13.8. No correlation was found between antigen CA-125 level and <jats:sup>68<\/jats:sup>Ga-PSMA expression. Range of tumor SUV<jats:sub>max<\/jats:sub> was not correlated with stage of disease. The remaining 62.5% (5\/8) were negative in <jats:sup>68<\/jats:sup>Ga-PSMA-11 PET\/CT, and histopathology confirmed benign pelvic tumor.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions<\/jats:title>\n            <jats:p>The initial experience supports the potential to use <jats:sup>68<\/jats:sup>Ga-PSMA-11 in ovarian cancer to differentiate malignant and benign tumors before surgery.<\/jats:p>\n            <jats:p>This study was approved by the Ethical Committee of the Medical University of Warsaw (KB\/2\/A\/2018).<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004486","type":"journal-article","created":{"date-parts":[[2022,12,13]],"date-time":"2022-12-13T20:00:09Z","timestamp":1670961609000},"page":"e60-e66","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["68Ga\u2013Prostate-Specific Membrane Antigen PET\/CT in Ovarian Tumors"],"prefix":"10.1097","volume":"48","author":[{"given":"Jolanta","family":"Kunikowska","sequence":"first","affiliation":[{"name":"Nuclear Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalena","family":"Bizo\u0144","sequence":"additional","affiliation":[{"name":"Department of Obstetrics, Gynecology, and Gynecological Oncology"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kacper","family":"Pe\u0142ka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pawe\u0142","family":"Derlatka","sequence":"additional","affiliation":[{"name":"Second Department of Obstetrics and Gynecology, Medical University of Warsaw"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Olszewski","sequence":"additional","affiliation":[{"name":"LUXMED Oncology Hospital, Warsaw, Poland."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leszek","family":"Kr\u00f3licki","sequence":"additional","affiliation":[{"name":"Nuclear Medicine Department"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","published-online":{"date-parts":[[2022,11,18]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1002\/uog.12323","article-title":"Improving strategies for diagnosing ovarian cancer: a summary of the international ovarian tumor analysis (IOTA) studies","volume":"41","year":"2013","journal-title":"Ultrasound Obstet Gynecol"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1002\/uog.11177","article-title":"Clinically oriented three-step strategy for assessment of adnexal pathology","volume":"40","year":"2012","journal-title":"Ultrasound Obstet Gynecol"},{"key":"bib3-20250621","first-page":"c6839","article-title":"Simple ultrasound rules to distinguish between benign and malignant adnexal masses before surgery: prospective validation by IOTA group","volume":"14","year":"2010","journal-title":"BMJ"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"3730","DOI":"10.3390\/cancers12123730","article-title":"CA125 and ovarian cancer: a comprehensive review","volume":"12","year":"2020","journal-title":"Cancer"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1056\/NEJMra041842","article-title":"Cancer of the ovary","volume":"351","year":"2004","journal-title":"N Engl J Med"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1007\/s12013-014-0463-x","article-title":"The diagnostic value of transvaginal sonograph (TVS), color Doppler, and serum tumor marker CA125, CEA, and AFP in ovarian cancer","volume":"72","year":"2015","journal-title":"Cell Biochem Biophys"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1002\/cncr.24149","article-title":"Role of surgical outcome as prognostic factor in advanced epithelial ovarian cancer: a combined exploratory analysis of 3 prospectively randomized phase 3 multicenter trials: by the Arbeitsgemeinschaft Gynaekologische Onkologie Studiengruppe Ovarialkarzinom (AGO-OVAR) and the Groupe d\u2019Investigateurs Nationaux pour les etudes des cancers de l\u2019Ovaire (GINECO)","volume":"115","year":"2009","journal-title":"Cancer"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","article-title":"The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer","volume":"108","year":"2008","journal-title":"Gynecol Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"1534","DOI":"10.1097\/IGC.0000000000001041","article-title":"European Society of Gynaecological Oncology (ESGO) guidelines for ovarian cancer surgery","volume":"27","year":"2017","journal-title":"Int J Gynecol Cancer"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1136\/ijgc-2021-002565","article-title":"ESGO\/ISUOG\/IOTA\/ESGE consensus statement on pre-operative diagnosis of ovarian tumors","volume":"31","year":"2021","journal-title":"Int J Gynecol Cancer"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1007\/s00261-021-03081-0","article-title":"Current update on malignant epithelial ovarian tumors","volume":"46","year":"2021","journal-title":"Abdom Radiol (NY)"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.ygyno.2009.10.059","article-title":"Diagnosis and staging of primary ovarian cancer: correlation between PET\/CT, Doppler US, and CT or MRI","volume":"116","year":"2010","journal-title":"Gynecol Oncol"},{"key":"bib13-20250621","doi-asserted-by":"crossref","first-page":"1912","DOI":"10.1007\/s00259-008-0890-2","article-title":"Diagnostic accuracy of integrated FDG-PET\/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT","volume":"35","year":"2008","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.suronc.2017.07.004","article-title":"The role of F18-FDG PET\/CT in predicting secondary optimal de-bulking in patients with recurrent ovarian cancer","volume":"26","year":"2017","journal-title":"Surg Oncol"},{"key":"bib15-20250621","first-page":"3629","article-title":"Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium","volume":"57","year":"1997","journal-title":"Cancer Res"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00259-020-05017-0","article-title":"[68 Ga]Ga-prostate-specific membrane antigen PET\/CT: a novel method for imaging patients with hepatocellular carcinoma","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"2199","DOI":"10.1007\/s00330-020-07318-2","article-title":"Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET\/CT as a new diagnostic avenue","volume":"31","year":"2021","journal-title":"Eur Radiol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10549-018-4717-y","article-title":"Prostate-specific membrane antigen in breast cancer: a comprehensive evaluation of expression and a case report of radionuclide therapy","volume":"169","year":"2018","journal-title":"Breast Cancer Res Treat"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13058-019-1205-1","article-title":"Targeting of prostate-specific membrane antigen for radio-ligand therapy of triple-negative breast cancer","volume":"21","year":"2019","journal-title":"Breast Cancer Res"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10585-018-9878-x","article-title":"Prostate-specific membrane antigen (PSMA) expression in breast cancer and its metastases","volume":"34","year":"2017","journal-title":"Clin Exp Metastasis"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1097\/PAI.0000000000000297","article-title":"Prostate-specific membrane antigen (PSMA) expression in the neovasculature of gynecologic malignancies: implications for PSMA-targeted therapy","volume":"25","year":"2017","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/RLU.0000000000002806","article-title":"68Ga\u2013prostate-specific membrane antigen-11 PET\/CT: a new imaging option for recurrent glioblastoma multiforme?","volume":"45","year":"2020","journal-title":"Clin Nucl Med"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1007\/s00268-005-0544-5","article-title":"Expression of prostate-specific membrane antigen in normal and malignant human tissues","volume":"30","year":"2006","journal-title":"World J Surg"},{"key":"bib24-20250621","first-page":"2669","article-title":"Selection of tumor antigens as targets for immune attack using immunohistochemistry: protein antigens","volume":"4","year":"1998","journal-title":"Clin Cancer Res"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/2326-6066.CIR-14-0192","article-title":"T cells bearing a chimeric antigen receptor against prostate-specific membrane antigen mediate vascular disruption and result in tumor regression","volume":"3","year":"2015","journal-title":"Cancer Immunol Res"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"871","DOI":"10.2967\/jnumed.117.203570","article-title":"Imaging of nonprostate cancers using PSMA-targeted radiotracers: rationale, current state of the field, and a call to arms","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s13550-021-00756-z","article-title":"A PSMA-targeted theranostic approach is unlikely to be efficient in serous ovarian cancers","volume":"11","year":"2021","journal-title":"EJNMMI Res"},{"key":"bib28-20250621","first-page":"76","article-title":"A giant ovarian mucinous tumor in a 58-year-old postmenopausal patient with persistent abdominal pain and high serum levels of CA 19-9","volume":"37","year":"2020","journal-title":"Pan Afr Med J"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1006\/gyno.2000.5811","article-title":"Serum CA 125, carcinoembryonic antigen, and CA 19-9 as tumor markers in borderline ovarian tumors","volume":"78","year":"2000","journal-title":"Gynecol Oncol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"105","DOI":"10.29271\/jcpsp.2019.02.105","article-title":"Diffusion-weighted magnetic resonance imaging (DWI) parameters in benign and malignant ovarian tumors with solid and cystic components","volume":"29","year":"2019","journal-title":"J Coll Physicians Surg Pak"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004486","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:01:48Z","timestamp":1750536108000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004486"}},"subtitle":["Potential to Differentiate Benign and Malignant Tumors Before Surgery: A Preliminary Report"],"short-title":[],"issued":{"date-parts":[[2022,11,18]]},"references-count":30,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004486","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11,18]]}}}